A high-throughput sequencing comparison between 92 ovarian cancer patients with low RPS6KA2 expression and 96 with high expression identified 617 upregulated and 6 downregulated genes in the high-expression cohort (Fig. 2G,H). This evidence concerns the gene RPS6KA2 and ovarian carcinoma.